论文部分内容阅读
目的探讨GP(吉西他滨+顺铂)化疗方案对肺癌患者术后肿瘤标志物表达的影响。方法回顾性分析2012年1月至2015年1月肺癌72例患者的临床资料,其中36例行GP方案辅助化疗为观察组,另36例行常规手术治疗为对照组,比较两组治疗前后血清肿瘤标志物的变化,如糖脂(CA125)、糖类抗原(CA19-9)、胚胎抗原(CEA)、同工酶(NSE)、细胞角蛋白19片段(CYFRA21-1)及鳞癌抗原(SCC)。结果两组CA125、CA19-9、CEA、NSE、CYFRA21-1、SCC水平治疗后均低于治疗前,差异均有统计学意义(P<0.05)。治疗后,观察组CA19-9(26.61±9.02)ng/ml、CEA(17.33±7.50)ng/ml、NSE(18.20±10.49)ng/ml、CYFRA21-1(2.59±0.22)ng/ml、SCC(2.62±1.18)μg/L均低于对照组(P<0.05)。结论 GP化疗方案能明显降低肺癌患者术后肿瘤标志物水平,安全性高,对于提高肺癌患者的生存期和减轻疾病困扰有重要意义。
Objective To investigate the effect of GP (gemcitabine + cisplatin) chemotherapy regimen on the expression of tumor markers in patients with lung cancer after operation. Methods The clinical data of 72 patients with lung cancer from January 2012 to January 2015 were retrospectively analyzed. Thirty-six patients received GP-adjuvant chemotherapy as the observation group and the other 36 patients received conventional surgery as the control group. The serum levels of Tumor markers such as carbohydrate lipids (CA125), carbohydrate antigen (CA19-9), embryonic antigen (CEA), isoenzyme (NSE), cytokeratin 19 fragment (CYFRA21-1) and squamous cell carcinoma antigen SCC). Results After treatment, the levels of CA125, CA19-9, CEA, NSE, CYFRA21-1 and SCC in both groups were significantly lower than those before treatment (P <0.05). The levels of CA19-9 (26.61 ± 9.02) ng / ml, CEA (17.33 ± 7.50) ng / ml, NSE (18.20 ± 10.49) ng / ml and CYFRA21-1 (2.59 ± 0.22) ng / (2.62 ± 1.18) μg / L were lower than the control group (P <0.05). Conclusion GP chemotherapy regimen can significantly reduce the level of tumor markers in patients with lung cancer after surgery, which is of great significance for improving the survival of patients with lung cancer and relieving diseases.